Somatostatin administration following pancreatoduodenectomy: a case-matched comparison according to surgical technique, body mass index, American Society of Anesthesiologists' score and Fistula Risk Score.
Aged
Aged, 80 and over
Anesthesiologists
/ organization & administration
Body Mass Index
Case-Control Studies
Female
Humans
Male
Middle Aged
Pancreatic Fistula
/ classification
Pancreaticoduodenectomy
/ adverse effects
Pancreaticojejunostomy
/ adverse effects
Postoperative Care
Postoperative Complications
/ classification
Retrospective Studies
Risk Factors
Societies, Medical
/ organization & administration
Somatostatin
/ administration & dosage
POPF
Pancreatoduodenectomy
Somatostatin analogues
Somatostatin prophylaxis
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
27
07
2020
accepted:
20
10
2020
pubmed:
4
12
2020
medline:
26
10
2021
entrez:
3
12
2020
Statut:
ppublish
Résumé
This study evaluated the controversial role of somatostatin after pancreatoduodenectomy (PD), stratifying patients for the main risk factors using the most recent postoperative pancreatic fistula (POPF) classification and including only patients who had undergone PD with the same technique of pancreatojejunostomy. Between November 2010 and February 2020, 218 PD procedures were carried out via personal modified pancreatojejunostomy (mPJ-PD). Somatostatin was routinely administered between 2010 and 2016, while from 2017, 97 mPJ-PD procedures without somatostatin (WS) were performed. The WS group was retrospectively compared with a control (C) group obtained with one-to-one case-control matching according to the body mass index, American Society of Anesthesiologists' score, and Fistula Risk Score (FRS). A total of 144 patients (72 WS group versus 72 C group) were compared. In the WS group. 6 patients (8.3%) developed clinically relevant POPF, compared with 8 patients (11.1%) in the C group (p = 0.656). In addition, on analyzing the subgroup of high-risk patients according to the FRS, we did not note any significant differences in POPF occurrence. Furthermore, no marked differences in the morbidity or mortality were found. Digestive bleeding and diabetes onset rates were higher in the WS group than in the control group, but not significantly so. The results of the present study confirm no benefit with the routine administration of somatostatin after PD to prevent POPF, even in high-risk patients. However, a possible role in the prevention of postoperative digestive bleeding and diabetes was observed.
Identifiants
pubmed: 33270148
doi: 10.1007/s00595-020-02189-y
pii: 10.1007/s00595-020-02189-y
pmc: PMC8141487
doi:
Substances chimiques
Somatostatin
51110-01-1
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1044-1053Références
Yoshioka R, Yasunaga H, Hasegawa K, Horiguchi H, Fushimi K, Aoki T, et al. Impact of hospital volume on hospital mortality, length of stay and total costs after pancreaticoduodenectomy. Br J Surg. 2014;101(5):523–9.
doi: 10.1002/bjs.9420
Pedrazzoli S. Pancreatoduodenectomy (PD) and postoperative pancreatic fistula (POPF). Med (United States). 2017. https://doi.org/10.1097/MD.0000000000006858 .
doi: 10.1097/MD.0000000000006858
Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138:8–13.
doi: 10.1016/j.surg.2005.05.001
Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584–91.
doi: 10.1016/j.surg.2016.11.014
Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CMA Jr. prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg. 2013;216(1):1–14.
doi: 10.1016/j.jamcollsurg.2012.09.002
Miller BC, Christein JD, Behrman SW, Drebin JA, Pratt WB, Callery MP, et al. A multi-institutional external validation of the Fistula Risk Score for pancreatoduodenectomy. J Gastrointest Surg. 2014;18(1):172–9 (discussion 179–80).
doi: 10.1007/s11605-013-2337-8
Shubert CR, Wagie AE, Farnell MB, Nagorney DM, Que FG, Lombardo KMR, et al. Clinical risk score to predict pancreatic fistula after pancreatoduodenectomy: independent external validation for open and laparoscopic approaches. J Am Coll Surg. 2015;221(3):689–98.
doi: 10.1016/j.jamcollsurg.2015.05.011
ASA House of Delegates/Executive Committee. Schaumburg (IL): American Society of Anesthesiologists; 2014. ASA physical status classification system [Internet]. Oct 15 [accessed 11 April 2020]. Available from https://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system .
Finlayson SR, Tosteson AN, Sharp SM, Warshaw AL, Fisher ES. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery. 1999;125:250–6.
doi: 10.1016/S0039-6060(99)70234-5
Gouma DJ, van Geenen RC, van Gulik TM, Thomas M, de Haan RJ, de Wit LT, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg. 2000;232:786–95.
doi: 10.1097/00000658-200012000-00007
Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10–5.
doi: 10.1097/01.sla.0000217673.04165.ea
Butturini G, Daskalaki D, Molinari E, Scopelliti F, Casarotto A, Bassi C. Pancreatic fistula: definition and current problems. J Hepatobiliary Pancreat Surg. 2008;15:247–51.
doi: 10.1007/s00534-007-1301-y
Poon RT, Lo SH, Fong D, Fan ST, Wong J. Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. Am J Surg. 2002;183:42–52.
doi: 10.1016/S0002-9610(01)00829-7
Klempa I, Schwedes U, Usadel KH. Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin. Chirurg. 1979;50:427–31.
pubmed: 477469
Shrikhande SV, Sivasanker M, Vollmer CM, Friess H, Besselink MG, Fingerhut A, et al. Pancreatic anastomosis after pancreatoduodenectomy: a position statement by the international study group of pancreatic surgery (ISGPS). Surgery. 2017;161:1221–34.
doi: 10.1016/j.surg.2016.11.021
Wiltberger G, Muhl B, Benzing C, Atanasov G, Hau HM, Horn M, et al. Preoperative risk stratification for major complications following pancreaticoduodenectomy. Int J Surg. 2016;31:33–9. https://doi.org/10.1016/j.ijsu.2016.04.034 .
doi: 10.1016/j.ijsu.2016.04.034
pubmed: 27126297
Morelli L, Di Franco G, Guadagni S, Palmeri M, Furbetta N, Gianardi D, et al. Technical details and results of a modified end-to-side technique of pancreatojejunostomy: a personal series of 100 patients. J Gastrointest Surg. 2017. https://doi.org/10.1007/s11605-017-3587-7 .
doi: 10.1007/s11605-017-3587-7
pubmed: 28936588
Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae .
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Wang SE, Chen SC, Shyr BU, Shyr YM. Comparison of Modified Blumgart pancreaticojejunostomy and pancreaticogastrostomy after pancreaticoduodenectomy. HPB (Oxford). 2016;18(3):229–35.
doi: 10.1016/j.hpb.2015.09.007
Kleespies A, Albertsmeier M, Obeidat F, Seeliger H, Jauch K-W, Bruns CJ. The challenge of pancreatic anastomosis. Langenbeck’s Arch Surg. 2008;393(4):459–71.
doi: 10.1007/s00423-008-0324-4
Grobmyer SR, Kooby D, Blumgart LH, Hochwald SN. Novel pancreaticojejunostomy with a low rate of anastomotic failure related complications. J Am Coll Surg. 2010;210(1):54–9.
doi: 10.1016/j.jamcollsurg.2009.09.020
Berberat PO, Friess H, Uhl W, Buchler MW. The role of octreotide in the prevention of complications following pancreatic resection. Digestion. 1999;60(Suppl 2):15–22.
doi: 10.1159/000051476
Ma LW, Dominguez-Rosado I, Gennarelli RL, Bach PB, Gonen M, D’Angelica MI, et al. The cost of postoperative pancreatic fistula versus the cost of pasireotide: results from a prospective randomized trial. Ann Surg. 2017;265(1):11–6.
doi: 10.1097/SLA.0000000000001892
Kurumboor P, Palaniswami KN, Pramil K, George D, Ponnambathayil S, Varma D, et al. Octreotide does not prevent pancreatic fistula following pancreatoduodenectomy in patients with soft pancreas and non-dilated duct: a prospective randomized controlled trial. J Gastrointest Surg. 2015;19(11):2038–44.
doi: 10.1007/s11605-015-2925-x
You DD, Paik KY, Park IY, Yoo YK. Randomized controlled study of the effect of octreotide on pancreatic exocrine secretion and pancreatic fistula after pancreatoduodenectomy. Asian J Surg. 2019;42(2):458–63.
doi: 10.1016/j.asjsur.2018.08.006
El Nakeeb A, ElGawalby A, Ali MA, Shehta A, Hamed H, El Refea M, et al. Efficacy of octreotide in the prevention of complications after pancreaticoduodenectomy in patients with soft pancreas and non-dilated pancreatic duct: a prospective randomized trial. Hepatobiliary Pancreat Dis Int. 2018;17(1):59–63.
doi: 10.1016/j.hbpd.2018.01.015
Yeo CJ, Cameron JL, Lillemoe KD, Sauter PK, Coleman J, Sohn TA, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg. 2000;232(3):419–29.
doi: 10.1097/00000658-200009000-00014
Lowy AM, Lee JE, Pisters PW, Davidson BS, Fenoglio CJ, Stanford P, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 1997;226(5):632–41.
doi: 10.1097/00000658-199711000-00008
Mungroop TH, van Rijssen LB, van Klaveren D, Smits FJ, van Woerden V, Linnemann RJ, et al. Alternative Fistula Risk Score for pancreatoduodenectomy (a-FRS): design and international external validation. Ann Surg. 2019;269(5):937–43.
doi: 10.1097/SLA.0000000000002620
Shamali A, Shelat V, Jaber B, Wardak A, Ahmed M, Fontana M, et al. Impact of obesity on short and long term results following a pancreatico-duodenectomy. Int J Surg. 2017;42:191–6.
doi: 10.1016/j.ijsu.2017.04.058
Adiamah A, Arif Z, Berti F, Singh S, Laskar N, Gomez D. The use of prophylactic somatostatin therapy following pancreaticoduodenectomy: a meta-analysis of randomised controlled trials. World J Surg. 2019;43(7):1788–801.
doi: 10.1007/s00268-019-04956-6
Sarr MG. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg. 2003;196(4):556–64.
doi: 10.1016/S1072-7515(03)00104-2
Allen PJ, Gonen M, Brennan MF, Bucknor AA, Robinson LM, Pappas MM, et al. Pasireotide for postoperative pancreatic fistula. N Engl J Med. 2014;370(21):2014–22.
doi: 10.1056/NEJMoa1313688
Katsourakis A, Oikonomou L, Chatzitheoklitos E, Noussios G, Pitiakoudis M, Polychronidis A, et al. The role of somatostatin in 67 consecutive pancreatectomies: a randomized clinical trial. Clin Exp Gastroenterol. 2010;3:179–83.
pubmed: 21694864
pmcid: 3108665
Li T, D’Cruz RT, Lim SY, Shelat VG. Somatostatin analogues and the risk of post-operative pancreatic fistulas after pancreatic resection—a systematic review and meta-analysis. Pancreatology. 2020. https://doi.org/10.1016/j.pan.2019.12.015 .
doi: 10.1016/j.pan.2019.12.015
pubmed: 33341341
Sandini M, Malleo G, Gianotti L. Scores for prediction of Fistula after pancreatoduodenectomy: a systematic review. Dig Surg. 2016;33:392–400. https://doi.org/10.1159/000445068 .
doi: 10.1159/000445068
pubmed: 27160158
Ellis RJ, Brock Hewitt D, Liu JB, Cohen NE, Merkow RP, Bentrem DJ, et al. Preoperative risk evaluation for pancreatic fistula after pancreaticoduodenectomy. J Surg Oncol. 2019;119:1128–34. https://doi.org/10.1002/jso.25464 .
doi: 10.1002/jso.25464
pubmed: 30951614
pmcid: 6894415
Gøtzsche PC, Hróbjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev. 2008;3:CD000193. https://doi.org/10.1002/14651858.CD000193.pub3 .
doi: 10.1002/14651858.CD000193.pub3
Benamouzig R, Benallaoua M, Saurin J-C, Boubaya L, Cellier C, Laugier R, et al. Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study. Ther Adv Gastroenterol. 2018;11:1–13. https://doi.org/10.1177/1756283X18756260 .
doi: 10.1177/1756283X18756260
Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. 1994;35(3 Suppl.):S1–4.
doi: 10.1136/gut.35.3_Suppl.S1
Samnegard H, Tyden G, Thulin L, Friman L, Uden R. Effect of somatostatin on regional splanchnic blood flows in man. Angiographic studies. Acta Chir Scand Suppl. 1980;500:71–3.
pubmed: 6111881
Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology. 1981;80:518–25.
doi: 10.1016/0016-5085(81)90014-7
Villanueva C, Ortiz J, Minana J, Soriano G, Sabat M, Boadas J, et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology. 2001;121:110–7.
doi: 10.1053/gast.2001.25536
Mc Millan MT, Christein JD, Callery MP, Behrman SW, Drebin JA, Kent TS, et al. Prophylactic octreotide for pancreatoduodenectomy: more harm than good? HPB. 2014;16:954–62.
doi: 10.1111/hpb.12314
Riveline JP, Boudou P, Blondeau B, Gautier JF. Glucagon-secretion inhibition using somatostatin: an old hormone for the treatment of diabetes-associated pancreatectomy. Diabetes Metab. 2017;43:269–71.
doi: 10.1016/j.diabet.2016.08.002
Lund A, Bagger JI, Wewer Albrechtsen NJ, Christensen M, Grøndahl M, Hartmann B, et al. Evidence of extrapancreatic glucagon secretion in man. Diabetes. 2016;65(3):585–97. https://doi.org/10.2337/db15-1541 .
doi: 10.2337/db15-1541
pubmed: 26672094
Bringer J, Mirouze J, Marchal G, et al. Glucagon immunoreactivity and antidiabetic action of somatostatin in the totally duodenopancreatectomized and gastrectomized human. Diabetes. 1981;30:851–6.
doi: 10.2337/diab.30.10.851
Okuma H, Bouchi R, Masuda S, Takeuchi T, Murakami M, Minami I, et al. Suppression of extrapancreatic glucagon by octreotide may reduce the fasting and postprandial glucose levels in a diabetic patient after total pancreatectomy. Intern Med. 2017;56(22):3061–6. https://doi.org/10.2169/internalmedicine.8963-17 .
doi: 10.2169/internalmedicine.8963-17
pubmed: 28943578
pmcid: 5725861